Wagner B K, Heaton A H, Flink J R
Pharmacy Service, United Hospital, St. Paul, MN 55102.
Ann Pharmacother. 1992 Feb;26(2):199-200. doi: 10.1177/106002809202600213.
To report a case of cefotetan disodium-induced hemolytic anemia.
Original research articles and case reports.
A 46-year-old woman developed fulminant hemolytic anemia following a second exposure to intravenous cefotetan disodium for postoperative prophylaxis. She developed respiratory failure requiring intubation and acute renal failure requiring hemodialysis. The hemolysis was successfully treated with plasmapheresis, but the patient died on the 25th postoperative day. Positive Coomb's tests have been reported in less than three percent of patients receiving cefotetan. To our knowledge, this is the first case of fulminant hemolytic anemia associated with intravenous cefotetan disodium therapy.
Cefotetan should be added to the list of drugs known to cause hemolytic anemia. Monitoring for hemolysis should be considered for patients who receive multiple courses of therapy.
报告1例头孢替坦二钠引起的溶血性贫血病例。
原始研究文章和病例报告。
一名46岁女性在第二次静脉注射头孢替坦二钠进行术后预防后发生暴发性溶血性贫血。她出现呼吸衰竭需要插管，以及急性肾衰竭需要血液透析。溶血通过血浆置换成功治疗，但患者在术后第25天死亡。接受头孢替坦治疗的患者中，抗人球蛋白试验阳性的报告不到3%。据我们所知，这是首例与静脉注射头孢替坦二钠治疗相关的暴发性溶血性贫血病例。
头孢替坦应添加到已知可引起溶血性贫血的药物清单中。对于接受多疗程治疗的患者，应考虑监测溶血情况。
Zotero 插件